Guidance reflects January 1 changes to Notifiable Conditions reporting

New guidance for reporting both Rapid Screening Test results and Deidentified Negative Screening Test results are now posted on the DOH Notifiable Conditions Rule Revision Implementation page.

• Rapid Screening Testing Reporting Guidance: Effective January 1, 2023, WAC 246-101-200 states an individual or entity including, but not limited to, health care providers and health care facilities, that conduct rapid screening tests for certain conditions (blood lead level testing, hepatitis C (acute and chronic infection), HIV infection, or COVID-19) meets the definition of a laboratory under the chapter and must fulfill the reporting requirements outlined in WAC 246-101-201 through 246-101-230.
• Deidentified Negative Screening Test Result Reporting Guidance: Effective January 1, 2023, WAC 246-101-201, lists the agents (conditions) that are notifiable by a laboratory director. Included in the list are chlamydia trachomatis, hepatitis C virus, human immunodeficiency virus (HIV), neisseria gonorrhoeae (gonorrhea), and treponema pallidum (syphilis).

The two guidance pages offer additional details, including overviews of the requirements and the reporting process. DOH will continue to update guidance as needed.